. 2022 Feb 10;12(2):29. doi: 10.1038/s41408-022-00620-w

Table 4.

Survival analysis in patients with stage I–II follicular lymphoma confirmed with positron emission tomography (PET) and bone marrow examination.

		Initial observation	Combined modality treatment	Radiation therapy alone	Systemic treatment
		(N = 55)	(N = 17)	(N = 63)	(N = 19)
OS since diagnosis	5-year (95% CI)	98.1% (0.945–1.000)	100.0% (1.000–1.000)	98.4% (0.952–1.000)	84.2% (0.693–1.000)
OS since diagnosis	HR^a (95% CI)	1.70 (0.38–7.71), p = 0.49	NA, p = 1.00	Reference	4.85 (1.05–22.36), p = 0.04
PFS since treatment	5-year (95% CI)	—	80.0% (0.621–1.000)	54.9% (0.438–0.688)	44.7% (0.268–0.748)
PFS since treatment	HR^a (95% CI)	—	0.39 (0.14–1.12), p = 0.08	Reference	1.50 (0.74–3.06), p = 0.26

^aHazard ratio and corresponding p-value was adjusted for the Follicular Lymphoma International Prognostic Index (FLIPI). OS overall survival, HR hazard ratio, Inf infinity, PFS progression-free survival.